摘要
目的分析医院药师关于患者出院带抗肿瘤药安全性的知识、态度及实践,探究可能存在的风险因素,为有针对性的开展肿瘤患者出院用药指导及合理用药提供参考。方法于2019年3月15日至2019年5月31日对中国31个省(市)各级医院的药师进行关于患者出院带抗肿瘤药安全性的问卷调查。结果药师抗肿瘤药相关知识的平均得分为46.7,相当于总分的51.8%。多数药师(74.5%)知晓出院带抗肿瘤药存在风险,并愿意(93.9%)为肿瘤患者提供用药指导。然而,药师对出院肿瘤患者的指导多局限于口头交代(62.1%),出院后患者求助医务人员的可及性普遍偏低(55.6%)。结论用药安全参与人员对患者出院带抗肿瘤药的安全风险重视不足、医院药师关于抗肿瘤药知识储备存在短板、患者用药教育没有完善的管理制度等均是威胁肿瘤患者出院后用药的风险因素。应认真寻找解决办法,不断提升患者出院带抗肿瘤药的安全性。
OBJECTIVE To analyze the knowledge,attitude and practice of hospital pharmacists on the safety of patients with anti-tumor drugs discharged from hospitals,explore possible risk factors,and provide reference for targeted guidance and rational medication of tumor patients discharged.METHODS From March 15,2019 to May-31,2019,pharmacists at hospitals in 31 provinces(cities)in China conducted a questionnaire survey on the safety of patients with anti-tumor drugs discharged from hospitals.RESULTS The average score of pharmacists;knowledges of anti-tumor drugs was 46.7,equivalent to 51.8%of the total score.Most pharmacists(74.5%)are aware of the risks of discharge of antineoplastic agents and are willing(93.9%)to provide medication guidance for cancer patients.However,the pharmacistsr guidance for patients with cancer on the discharge was mostly limited to oral presentation(62.1%),and the accessibility of pharmacists to cancer patients after discharge was generally low(55.6%).CONCLUSION Drug safety participants pay insufficient attention to the safety risks of patients with anticancer drugs discharged,and hospital pharmacists#knowledge reserve of anti-tumor drugs has shortcomings,there is no perfect system of medication education for discharged patients,which are all risk factors threatening the safety of medication for cancer patients after discharge.Serious efforts should be made to find solutions to continuously improve the safety of patients with anticancer drugs discharged from hospitals.
作者
杨玉慧
许秀丽
朱珠
YANG Yu-hui;XU Xiu-li;ZHU Zhu(Department of Pharmacy,Peking Union Medical College Hospital Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2020年第6期480-485,共6页
Chinese Pharmaceutical Journal
基金
中华医学会临床药学分会-吴阶平医学基金会科研专项基金项目资助(320.6750.19090-30)。